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EXPERIENCE WITH INTRA-CAVITARY RADIOGOLD
AT HENRY FORD HOSPITAL
M . J. BRENNAN,

M.D.*

K. D. M C G I N N I S , M.D.**
L. PREUSS, M.S.***

Radiogold was introduced into therapy for effusion at Henry Ford Hospital in
March, 1952. Since that time 42 patients have received injections of colloidal gold
(Au'™) into serosal cavities for the palliation of serosal effusions secondary to malignant processes. Au'" has been used because of its suitable half-life of 2.7 days and its
radiation characteristics. This isotope emits a beta particle with an average energy of
0.97 MEV and a gamma component of 0.41 MEV. The beta emission has a mean path
in tissue of 3.8 mm and is responsible for therapeutic effect. The gamma emission is
responsible for the chief health hazards involved in the clinical use of Au™.
Methods and Dosage: Methods for safe-handling of radiogold have been described
elsewhere',^. Exposure for the physician during the process of administration usually
does not exceed 20 milliroentgens by direct measurement. This level is well within
the maximum permissible daily exposure of 50 milliroentgens. The patients have been
kept in private rooms until the residual radio-activity was less than 30 mfllicuries of
gold; individually calculated time-distance precautions are provided for the protection
of medical and nursing personnel, and visitors, during the post-administration period.
Single doses ranged from 75 to 150 mfllicuries in the twenty patients who were
given intraperitoneal gold and who lived more than one month following the instfllation
of gold. There was no correlation of length or frequency of good effect with dose in
the intraperitoneal group. (Table I ) The present series is not large enough to establish
optimal dose levels. However, Kniseley^ failed to find pathological evidence of acute
radiation complication in patients given gold in quantities as large as 659 mfllicuries
intraperitoneally in ten months. Five of the seven patients given 150 mfllicuries intraabdominally in this series had good results, while three of five given 75 mfllicuries had
good results. In view of the lack of knowledge concerning mechanism of action of
radiogold and the desire of insuring adequate dosage, the large amounts have been
preferred inasmuch as no radiation complication occurred in this entire series of 42
treatments.
Results:
Only patients who survived more than three months under observation have been
considered in the calculation of determinate results.
ASCITES GROUP
Determinate Good Results:
Determinate good results are restricted to those patients who, having previously
required paracentesis, experienced control of their effusion for more than three months
following gold instfllation. By control is meant freedom from the necessity for para*Oncology Division
••Department of Radiology
***Edsel B. Ford Institute for Medical Research
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centesis for a minimum period of three months. Six of the definitive good results noted
in Table I remained free of ascites from six to thirteen months. Four cases required
paracentesis again at three and one-half, four, five and six months respectively.
TABLE I
ASCITES GROUP OF THIRTY PATIENTS. SINGLE INTRAPERITONEAL INJECTION OF
RADIOACTIVE GOLD WITH RESULT
150 mc.
Ovary
Definitive
Good
Results
(10)

75 mc.

50 mc.

Ovary
Adenoma Ca.

Mesothelioma

Endo.melrial Ca.

Schwannoma
Breast
125 mc.

100 mc.

125 mc.

100 mc.

75 mc.

50 mc.

75 mc.

50 mc.

Ovary

150 mc.
Ovary
Prophylactic
(6)

100 mc.
Ovary

Ovary

150 mc.
Probable
Good
Results
(1)

125 mc.
Ovary

Ovary

Adeno Ca.
Stomach

Ovary
Ovary
Ovary
150 mc.

Failures
(4)

100 mc.
Ovary

75 mc.

50 mc.

Ovary
Colon

150 mc.

Indeterminate

125 mc.
Ovary

125 mc.

100 mc.

Ovary

Ovary

Renal

Ovary

(Ml

Ovary

(6 dead)

Ovary

75 mc.

50 mc.

Fibrosarcoma

Ovary

Pancreas

Probable Good Results:
Probable good results are tabulated for a group of patients observed from a
minimum of five to a maximum of twelve weeks after therapy. One such patient is
apparently well controlled seven weeks foflowing the administration of radiogold and
no longer has demonstrable peritoneal effusion.
Prophylactic Group:
Six patients without ascfles were given intraperitoneal gold prophylactically when
surgery disclosed ovarian carcinoma already involving the peritoneum in five, and
carcinoma of the stomach metastatic to the ovary in one. Of these patients three
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remain free of ascites five, six and fifteen months after gold treatment. Two patients
died after two and six months, respectively, of progression of intra-abdominal disease
demonstrated at autopsy. Nevertheless, they remained free of ascites until death.
In a sixth case death occurred six months after gold treatment, but paracentesis was
not needed until one week before demise.
Failures:
Definitive failures are those in which adequate time for development of therapeutic
benefit has clasped and in whom paracentesis has continued to be necessary at intervals
of three weeks or less following radioactive gold treatment. Four such patients were
seen.
Indeterminate:
Cases are designated as indeterminate when death or loss from follow-up occurred
within one month of the time of administration of gold. This time is considered too
short for the success or failure of treatment to become apparent. Seven patients who
died within this time interval and three whose records are incomplete are included in
this category.
PLEURAL EFFUSIONS
The intrathoracic group has been divided into categories constructed on the same
criteria as those explained above for the ascites group. Results in these patients are
seen in Table I I . Dosages in this group ranged from 50 to 75 mc.
TABLE I I
PLEURAL EFFUSION GROUP OF TWELVE PATIENTS. SINGLE INTRAPLEURAL
INJECTION OF RADIOACTIVE GOLD WITH RESULT
75 mc.

Millicuries Radiogold
Definitive

1

Breast

50 mc.
Breast
Mesothelioma

Good
Results
(3)
75 mc.
Probable Good

50 mc.

Breast

Results
(1)
75 mc.
Failures

50 mc.

Breast

(1)
75 inc.
Indeterminate
(7)

Breast
Breast
Colon
Thyroid
Adeno Ca.
Cervix

9!

50 m.c.
Breast

COMPLICATIONS
One patient developed generalized coliform peritonitis immediately after paracentesis for gold therapy and died four days later. This patient was autopsied, but
evidence of bowel perforation was lacking and the gold was found evenly distributed
throughout the peritoneal cavity without intensive local effects at any point. The
possibility that gold interfered with the patient's defense against peritonitis, attributable
most probably to the paracentesis itself, cannot be excluded. Although Botsford''
has recorded bone marrow hypoplasia with areas of focal necrosis following intracavitary
radiogold, in no instance in this series was leukopenia seen and the patients remained
free of thrombocytopenia and hemorrhagic manifestations. In those patients who were
followed for a long period of time no evidence of late radiation anemia developed.
DISCUSSION
Examination of recorded clinical data undertaken for the purpose of finding information of prognostic value with regard to the probable usefulness of radiogold in
the treatment of ascites shows that the most responsive group of patients are those who
present with relatively early disease as manifested by a lack of hepatomegaly, absence
of palpable abdominal masses and absence of blood in the serosal aspirate. Experience
here substantiates the findings of others with respect to the usefulness of this mode
of therapy' ''''^ in the management of ascites due to malignant disease.
The efficacy of radiogold in controlling effusion due to metastatic malignancy
is not derived from actual control of the disease process itself as is revealed in two of
the prophylactic cases who, in spite of progression of intra-abdominal disease, continued to have control of ascites. While Goldie and Hahn'" observed destruction of
sarcoma 37 cefls intraperitoneally in the CFW mouse following intraperitoneal gold,
Stembridge has shown that carcinoma cells persist in apparently viable state after gold
infusion even though ascites does not recur." Autopsy studies have demonstrated extensive superficial fibrotic change in tumor and in the serosa itself in patients treated
with radiogold.' There is no evidence of effect on malignant cells lying more than 2 or
3 mm. below the surface.'
Therefore, when sterflization of serosal metastases is being attempted, intracavitary
gold may be thought of as a supplement, but certainly not a substitute, for external
irradiation.
The tolerance of patients for abdominal irradiation given in close temporal proximity to radiogold treatment has not been determined. Therefore, one would hesitate
to give intraperitoneal gold if it is thought that definitive radiation treatment rather
than simple palliation is feasible.

SUMMARY
1. Intracavitary radiogold has proved useful for the palliation of malignant ascites and hydrothorax.
2.

No complications attributable to radiation were seen in this series.

3.

Effusion due to very far advanced malignancy, particularly in the presence of
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hepatomegaly, palpable tumor masses and grossly blood fluid is seldom controlled by
radiogold infusion.
4. Prophylactic use of radiogold appears to have been successful in delaying the
complication of ascites in ovarian malignancy.
The authors wish to express their appreciation to Dr. A. Veldhuis for permission to use cases
treated in the Gynecological Section in this study.
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